A decision on whether to subsidise a CBD medicine that fights severe epilepsy in children has been deferred despite health professionals accepting cannabidiol is “likely to be beneficial”.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

The Pharmaceutical Benefits Advisory Committee (PBAC) said it was delaying a verdict on Epidyolex to enable further consultations to take place.

Steve has reported for a number of consumer and B2B titles over a journalism career spanning more than three decades. He is a regulator contributor to health journal, The Medical Republic, writing on...